Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab Injection-Site Pain Study
NCT03848403Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ixekizumab in plaque psoriasis (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Injection Pain Visual Analog Scale at Day 15. Started Jan 2019; status: terminated.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03848403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848403.